Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9844172 | 0.88 | TDP1 (0.64) | TDP1LMNASCN1ASCN2ASCN3A | |
| SCHEMBL12487561 | 0.84 | HPGD (0.55) | TDP1LMNAALDH1A1L3MBTL1HPGD | |
| SCHEMBL28036335 | 0.82 | TDP1 (0.56) | TDP1LMNASCN1ASCN2ASCN3A | |
| SCHEMBL6662971 | 0.82 | TDP1 (0.65) | TDP1LMNASCN1ASCN2ASCN3A | |
| SCHEMBL12959086 | 0.81 | NPC1 (0.53) | TDP1LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL10857542 | 0.79 | HPGD (0.44) | TDP1SCN1ASCN2ASCN3AALDH1A1 | |
| SCHEMBL27898323 | 0.78 | TDP1 (0.58) | TDP1LMNASCN1ASCN2ASCN3A | |
| SCHEMBL21820641 | 0.77 | TDP1 (0.71) | TDP1LMNASCN1ASCN2ASCN3A | |
| SCHEMBL223441 | 0.77 | TDP1 (1.00) | TDP1LMNAALDH1A1KMT2AMAPK1 | |
| SCHEMBL416566 | 0.77 | TDP1 (0.91) | TDP1LMNAALDH1A1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | UNIV KYOTO (JP) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | TDP1 4802/4885LMNA 3022/4885SCN1A 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.